Cargando…
Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis
OBJECTIVE: To test whether inhibition of sclerostin by a targeted monoclonal antibody (Scl-Ab) protects from bone and cartilage damage in inflammatory arthritis. Sclerostin is a potent inhibitor of bone formation and may be responsible for the low level of bone repair in patients with rheumatoid art...
Autores principales: | Chen, Xiao-Xiang, Baum, Wolfgang, Dwyer, Denise, Stock, Michael, Schwabe, Kay, Ke, Hua-Zhu, Stolina, Marina, Schett, Georg, Bozec, Aline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786639/ https://www.ncbi.nlm.nih.gov/pubmed/23666928 http://dx.doi.org/10.1136/annrheumdis-2013-203345 |
Ejemplares similares
-
How Autoantibodies Regulate Osteoclast Induced Bone Loss in Rheumatoid Arthritis
por: Steffen, Ulrike, et al.
Publicado: (2019) -
Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis
por: Koenen, Mascha, et al.
Publicado: (2018) -
Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study
por: Marenzana, Massimo, et al.
Publicado: (2013) -
Periarticular Bone Loss in Antigen-Induced Arthritis
por: Engdahl, Cecilia, et al.
Publicado: (2013) -
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies
por: Stolina, Marina, et al.
Publicado: (2009)